For the quarter ending 2025-09-30, BTAI has $44,792K in assets. $133,711K in debts. $36,176K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 36,176 | 17,435 | ||
| Restricted cash | 1,144 | 1,140 | ||
| Accounts receivable, net | 0 | 17 | ||
| Inventory | 459 | 506 | ||
| Prepaid expenses | 5,690 | 5,150 | ||
| Other current assets | 934 | 995 | ||
| Total current assets | 44,403 | 25,243 | ||
| Property and equipment, net | 249 | 324 | ||
| Operating lease right-of-use assets | 140 | 222 | ||
| Other assets | 0 | - | ||
| Total assets | 44,792 | 25,789 | ||
| Accounts payable | 16,276 | 16,692 | ||
| Accrued expenses | 4,363 | 5,090 | ||
| Current portion of long-term debt | 16,823 | 11,216 | ||
| Other current liabilities-Related Party | 122 | 122 | ||
| Other current liabilities-Nonrelated Party | 220 | 256 | ||
| Total current liabilities | 37,804 | 33,376 | ||
| Long-term portion of operating lease liabilities | 0 | - | ||
| Derivative liabilities | 3,605 | 2,611 | ||
| Long-term debt | 92,302 | 97,469 | ||
| Total liabilities | 133,711 | 133,456 | ||
| Common stock, 0.001 par value, 200,000 shares authorized as of september 30, 2025 and december 31, 2024 19,996 and 3,102 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 73 | 60 | ||
| Additional paid-in-capital | 618,557 | 568,911 | ||
| Accumulated deficit | -707,549 | -676,638 | ||
| Total stockholders' (deficit) equity | -88,919 | -107,667 | ||
| Total liabilities and stockholders' (deficit) equity | 44,792 | 25,789 | ||
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)